ReviewCurrent HIV/AIDS reports2019
Neurocognitive Phenotyping of HIV in the Era of Antiretroviral Therapy.
Review in Current HIV/AIDS reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Is There Any Evidence of Premature, Accentuated and Accelerated Aging Effects on Neurocognition in People Living with HIV? A Systematic Review.AIDS and behavior · 2021Pooled it
- Implications and prospects of immunological and neuroimaging research in HIV-associated neurocognitive disorders.Frontiers in neurologyPooled it
- KYNA Ameliorates Glutamate Toxicity of HAND by Enhancing Glutamate Uptake in A2 Astrocytes.International journal of molecular sciences · 2024Article
- Cognitive impairment and neurocognitive profiles among people living with HIV and HIV-negative individuals older over 50 years: a comparison of IHDS, MMSE and MoCA.Journal of neurovirology · 2024Article
- Latent Profile Analysis of Cognitive Performance and Depressive Symptoms Among People with HIV.AIDS patient care and STDs · 2024Article
- Mental health phenotypes of well-controlled HIV in Uganda.Frontiers in public health · 2024Article
- NRF2 Antagonizes HIV-1 Tat and Methamphetamine-Induced BV2 Cell Ferroptosis by Regulating SLC7A11.Neurotoxicity research · 2023Article
- Pharmacotherapeutic profile, polypharmacy and its associated factors in a cohort of people living with HIV in Brazil.AIDS research and therapy · 2023Article
- Review
- Rich-Club Analysis of Structural Brain Network Alterations in HIV Positive Patients With Fully Suppressed Plasma Viral Loads.Frontiers in neurology · 2022Article
- Longitudinal telomere length profile does not reflect HIV and childhood trauma impacts on cognitive function in South African women.Journal of neurovirology · 2021Article
- Neuroimaging the Neuropathogenesis of HIV.Current HIV/AIDS reports · 2021Review
- Reliably Measuring Cognitive Change in the Era of Chronic HIV Infection and Chronic HIV-Associated Neurocognitive Disorders.Current topics in behavioral neurosciences · 2021Review
- Deep Phenotyping of HIV Neurocognitive Complications Among Individuals Residing in High-Income Countries.Current topics in behavioral neurosciences · 2021Article
- Neuropsychiatric Disorders, Emotional Disturbances, and Their Associations with HIV-Associated Neurocognitive Disorder.Current topics in behavioral neurosciences · 2021Review
- The association of peripheral immune markers with brain cortical thickness and surface area in South African people living with HIV.Journal of neurovirology · 2020Article
- Lifetime antiretroviral exposure and neurocognitive impairment in HIV.Journal of neurovirology · 2020Article
- Brain amyloid in virally suppressed HIV-associated neurocognitive disorder.Neurology(R) neuroimmunology & neuroinflammation · 2020Article
- Pharmacological Inhibition of PPARy Boosts HIV Reactivation and Th17 Effector Functions, While Preventing Progeny Virion Release and dePathogens & immunity · 2020Article
- Astrocyte HIV-1 Tat Differentially Modulates Behavior and Brain MMP/TIMP Balance During Short and Prolonged Induction in Transgenic Mice.Frontiers in neurology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
purpose of reviewThis paper examines the theoretical and empirical basis for neurocognitive phenotyping of HIV. RECENT
findingsThe pattern of neurocognitive symptoms associated with HIV has traditionally been referred to as a "subcortical" phenotype. Recent concern has been raised that the neurocognitive phenotype in the post-ART era has changed to reflect the addition of cortical features, suggestive of synergistic age-related neurodegeneration. Empirical evidence reviewed in this paper suggests that, when present, HIV-related neurocognitive impairment in the post-ART era remains subcortical in nature, regardless of advanced age or treatment status. Persistent neurocognitive impairment among virally suppressed individuals may reflect a combination of HIV disease factors, pre-existing risk factors, and/or emergent health comorbidities such as subcortical ischemic vascular disease in older people living with HIV. An entrenchment of the subcortical neurocognitive phenotype of HIV appears to be unfolding in the post-ART era. Whether new neurocognitive subtypes of HIV exist in the current era requires additional research utilizing harmonized test protocols and advanced computational methods capable of deep phenotyping. Recommendations from other neurological disorders are provided.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.